NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 15 of 16 cases where NIVF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for NIVF just turned positive on October 02, 2026. Looking at past instances where NIVF's MACD turned positive, the stock continued to rise in 7 of 11 cases over the following month. The odds of a continued upward trend are 64%.
Following a +13.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in 67 of 80 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIVF entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.014) is normal, around the industry mean (204.132). P/E Ratio (0.000) is within average values for comparable stocks, (18.957). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.100) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for PIII turned positive on October 22, 2026. Looking at past instances where PIII's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PIII's RSI Indicator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +9.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PIII advanced for three days, in 197 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PIII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PIII declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PIII entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.185) is normal, around the industry mean (204.132). P/E Ratio (-0.132) is within average values for comparable stocks, (18.957). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.100) among similar stocks. P/S Ratio (0.017) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. PIII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PIII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
| NIVF | PIII | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 76% |
| Stochastic ODDS (%) | 1 day ago 87% | N/A |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 4 days ago 84% | 1 day ago 85% |
| Declines ODDS (%) | 1 day ago 90% | 10 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NIVF’s FA Score shows that 1 FA rating(s) are green while PIII’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NIVF’s TA Score shows that 5 TA indicator(s) are bullish while PIII’s TA Score has 3 bullish TA indicator(s).
NIVF (@Hospital/Nursing Management) experienced а -35.81% price change this week, while PIII (@Hospital/Nursing Management) price change was -5.95% for the same time period.
The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was +1.15%. For the same industry, the average monthly price growth was -3.02%, and the average quarterly price growth was +22.32%.
PIII is expected to report earnings on Nov 12, 2026.
Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.
A.I.dvisor tells us that NIVF and UHS have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NIVF and UHS's prices will move in lockstep.
| Ticker / NAME | Correlation To NIVF | 1D Price Change % | ||
|---|---|---|---|---|
| NIVF | 100% | -20.97% | ||
| UHS - NIVF | 7% Poorly correlated | +2.88% | ||
| ASTH - NIVF | 7% Poorly correlated | +1.77% | ||
| PIII - NIVF | 6% Poorly correlated | +6.08% | ||
| DVA - NIVF | 4% Poorly correlated | +5.25% | ||
| GRDN - NIVF | 4% Poorly correlated | +1.56% | ||
More | ||||
A.I.dvisor tells us that PIII and ADUS have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PIII and ADUS's prices will move in lockstep.
| Ticker / NAME | Correlation To PIII | 1D Price Change % | ||
|---|---|---|---|---|
| PIII | 100% | +6.08% | ||
| ADUS - PIII | 24% Poorly correlated | +4.00% | ||
| SGRY - PIII | 23% Poorly correlated | +3.25% | ||
| ENSG - PIII | 21% Poorly correlated | +2.88% | ||
| OPCH - PIII | 21% Poorly correlated | N/A | ||
| HCSG - PIII | 21% Poorly correlated | +14.19% | ||
More | ||||